Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease

• Published in: The American heart journal Vol. 146; no. 6; pp. 1022 - 1027
• Main Authors: Kondo, Junichiro, Sone, Takahito, Tsuboi, Hideyuki, Mukawa, Hiroaki, Morishima, Itsuro, Uesugi, Michitaka, Kono, Tomohiro, Kosaka, Takashi, Yoshida, Tomohiro, Numaguchi, Yasushi, Matsui, Hideo, Murohara, Toyoaki, Okumura, Kenji
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01-12-2003; Elsevier Limited
• Subjects: Aged; Angina Pectoris - etiology; Angina Pectoris - prevention & control; Angiotensin Receptor Antagonists; Benzimidazoles - therapeutic use; Blood pressure; Cardiovascular disease; Cholesterol; Coronary Disease - drug therapy; Death, Sudden, Cardiac; Drug therapy; Enzymes; Female; Heart attacks; Heart failure; Heart Failure - etiology; Heart Failure - prevention & control; Humans; Male; Mortality; Myocardial Infarction - mortality; Myocardial Infarction - prevention & control; Myocardial Revascularization; Patients; Prospective Studies; Risk factors; Statins; Statistics as Topic; Tetrazoles - therapeutic use; Triglycerides
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/S0002-8703(03)00443-5

The purpose of this study was to investigate the effects of angiotensin II receptor blockers on the prevention of cardiovascular events in patients with coronary artery disease (CAD).
Angiotensin II may contribute to the pathogenesis of CAD. Long-term clinical trials have shown that blockade of the renin-angiotensin system can reduce cardiovascular events in patients with acute myocardial infarction complicated by heart failure.
Patients with a history of coronary intervention and no significant coronary stenosis on follow-up angiography 6 months after intervention were randomly assigned into a candesartan group (n = 203; baseline treatment plus candesartan 4 mg/d) or a control group (n = 203; baseline treatment alone). The primary end point was a composite of revascularization, nonfatal myocardial infarction, or cardiovascular death. The secondary end point was hospitalization for cardiovascular causes.
There were no changes in blood pressure and in other coronary risk factors in either group during a mean follow-up of 24 months. Primary end point risk was significantly lower in the candesartan group (n = 12) than in control group patients (n = 25) (
P = .03). Candesartan treatment reduced primary end point risk (5.9% vs 12.3% for control subjects; relative risk, 0.47; 95% CI, 0.24 to 0.93). The incidence of all events including secondary end points and noncardiovascular death was significantly lower in the candesartan group than in control group patients (23 vs 40 cases) (
P = .02).
Relatively low-dose candesartan, which did not alter blood pressure levels, reduces cardiovascular risk in high-risk patients with CAD.